BACKGROUND: It is unclear whether circulating antibody levels conferred protection against SARS-CoV-2 infection among patients receiving dialysis during the Omicron-dominant period. METHODS: We followed monthly semiquantitative SARS-CoV-2 RBD IgG index values in a randomly selected nationwide cohort of patients receiving dialysis and ascertained SARS-CoV-2 infection during the Omicron-dominant period of December 25, 2021 to January 31, 2022 using electronic health records. We estimated the relative risk for documented SARS-CoV-2 infection by vaccination status and by circulating RBD IgG using a log-binomial model accounting for age, sex, and prior COVID-19. RESULTS: Among 3576 patients receiving dialysis, 901 (25%) received a third mRNA vaccine dose as of December 24, 2021. Early antibody responses to third doses were robust (median peak index IgG value at assay limit of 150). During the Omicron-dominant period, SARS-CoV-2 infection was documented in 340 (7%) patients. Risk for infection was higher among patients without vaccination and with one to two doses (RR, 2.1; 95% CI, 1.6 to 2.8, and RR, 1.3; 95% CI, 1.0 to 1.8 versus three doses, respectively). Irrespective of the number of vaccine doses, risk for infection was higher among patients with circulating RBD IgG <23 (506 BAU/ml) (RR range, 2.1 to 3.2, 95% CI, 1.3 to 3.4 and 95% CI, 2.2 to 4.5, respectively) compared with RBD IgG ≥23. CONCLUSIONS: Among patients receiving dialysis, a third mRNA vaccine dose enhanced protection against SARS-CoV-2 infection during the Omicron-dominant period, but a low circulating RBD antibody response was associated with risk for infection independent of the number of vaccine doses. Measuring circulating antibody levels in this high-risk group could inform optimal timing of vaccination and other measures to reduce risk of SARS-CoV-2 infection.
BACKGROUND: It is unclear whether circulating antibody levels conferred protection against SARS-CoV-2 infection among patients receiving dialysis during the Omicron-dominant period. METHODS: We followed monthly semiquantitative SARS-CoV-2 RBD IgG index values in a randomly selected nationwide cohort of patients receiving dialysis and ascertained SARS-CoV-2 infection during the Omicron-dominant period of December 25, 2021 to January 31, 2022 using electronic health records. We estimated the relative risk for documented SARS-CoV-2 infection by vaccination status and by circulating RBD IgG using a log-binomial model accounting for age, sex, and prior COVID-19. RESULTS: Among 3576 patients receiving dialysis, 901 (25%) received a third mRNA vaccine dose as of December 24, 2021. Early antibody responses to third doses were robust (median peak index IgG value at assay limit of 150). During the Omicron-dominant period, SARS-CoV-2 infection was documented in 340 (7%) patients. Risk for infection was higher among patients without vaccination and with one to two doses (RR, 2.1; 95% CI, 1.6 to 2.8, and RR, 1.3; 95% CI, 1.0 to 1.8 versus three doses, respectively). Irrespective of the number of vaccine doses, risk for infection was higher among patients with circulating RBD IgG <23 (506 BAU/ml) (RR range, 2.1 to 3.2, 95% CI, 1.3 to 3.4 and 95% CI, 2.2 to 4.5, respectively) compared with RBD IgG ≥23. CONCLUSIONS: Among patients receiving dialysis, a third mRNA vaccine dose enhanced protection against SARS-CoV-2 infection during the Omicron-dominant period, but a low circulating RBD antibody response was associated with risk for infection independent of the number of vaccine doses. Measuring circulating antibody levels in this high-risk group could inform optimal timing of vaccination and other measures to reduce risk of SARS-CoV-2 infection.
Authors: Richard W Corbett; Sarah Blakey; Dorothea Nitsch; Marina Loucaidou; Adam McLean; Neill Duncan; Damien R Ashby Journal: J Am Soc Nephrol Date: 2020-06-19 Impact factor: 10.121
Authors: Shuchi Anand; Maria E Montez-Rath; Jialin Han; Pablo Garcia; LinaCel Cadden; Patti Hunsader; Russell Kerschmann; Paul Beyer; Mary Dittrich; Geoffrey A Block; Scott D Boyd; Julie Parsonnet; Glenn M Chertow Journal: J Am Soc Nephrol Date: 2021-06-11 Impact factor: 14.978
Authors: Shuchi Anand; Maria E Montez-Rath; Jialin Han; Pablo Garcia; LinaCel Cadden; Patti Hunsader; Curt Morgan; Russell Kerschmann; Paul Beyer; Mary Dittrich; Geoffrey A Block; Glenn M Chertow; Julie Parsonnet Journal: Ann Intern Med Date: 2021-12-14 Impact factor: 51.598
Authors: Stephen Salerno; Joseph M Messana; Garrett W Gremel; Claudia Dahlerus; Richard A Hirth; Peisong Han; Jonathan H Segal; Tao Xu; Dan Shaffer; Amy Jiao; Jeremiah Simon; Lan Tong; Karen Wisniewski; Tammie Nahra; Robin Padilla; Kathryn Sleeman; Tempie Shearon; Sandra Callard; Alexander Yaldo; Lisa Borowicz; Wilfred Agbenyikey; Golden M Horton; Jesse Roach; Yi Li Journal: JAMA Netw Open Date: 2021-11-01
Authors: Teresa Lambe; Andrew J Pollard; Merryn Voysey; Shuo Feng; Daniel J Phillips; Thomas White; Homesh Sayal; Parvinder K Aley; Sagida Bibi; Christina Dold; Michelle Fuskova; Sarah C Gilbert; Ian Hirsch; Holly E Humphries; Brett Jepson; Elizabeth J Kelly; Emma Plested; Kathryn Shoemaker; Kelly M Thomas; Johan Vekemans; Tonya L Villafana Journal: Nat Med Date: 2021-09-29 Impact factor: 53.440
Authors: Samuel M Ailsworth; Behnam Keshavarz; Nathan E Richards; Lisa J Workman; Deborah D Murphy; Michael R Nelson; Thomas A E Platts-Mills; Jeffrey M Wilson Journal: Ann Allergy Asthma Immunol Date: 2022-10-11 Impact factor: 6.248